Sanofi controversy: "There are still a lot of treatments that are not accessible to all populations"
Audio 4:50
By: Jean-Baptiste Marot Follow
In an interview with Bloomberg on Wednesday, Sanofi chief executive Paul Hudson said that the United States, the first country to have financially supported the laboratory on Covid-19, would be given priority in the event of a vaccine discovery . Especially since Sanofi criticizes the European Union for its lack of cooperation and investment. Faced with the outcry provoked by this declaration, the boss of Sanofi France wanted to clear up the controversy. The pharmaceutical giant Sanofi will not give priority to the United States of a possible vaccine against Covid-19 if the European Union is also "effective" to finance its development. To talk about it, Nathalie Coutinet, health economist, lecturer-researcher at the Sorbonne Paris Nord University and member of the collective of Economistes Atterrés.
Publicity
" It is shocking. We want to say that a vaccine must be accessible to all. But this would not be the first time that we have been in the case of parts of the world population excluded from treatment. "
Newsletter Receive all international news directly in your mailbox
I subscribeFollow all international news by downloading the RFI application
google-play-badge_FR- Coronavirus
- Health and Medicine
- France
- United States
- European Union
- Economy
On the same subject
Covid-19 vaccine: Sanofi benefits the United States and creates controversy
Coronavirus: Sanofi promises a donation of 100 million doses of hydroxychloroquine
Coronavirus: Washington accuses Beijing of trying to hack vaccine research